Independent in-depth research from Finimize, Finimize

Finimize Research

Independent, in-depth research from Finimize, combining bottom-up and top-down fundamental analysis to identify investment opportunities.

Reda Farran, CFA. Started as a sell-side equity analyst before joining an investment consultancy to help institutional investors with portfolio allocation and optimization. After that, Reda spent more than 4 years as an equity analyst at Fidelity, researching and investing in stocks across 5 different sectors including green energy and utilities.


Russell Burns, MBA. Has over 25 years experience at investment banks in London and Tokyo, a Japan-based hedge fund, and a special situations advisory firm. He uses bottom-up and top-down analysis to identify investment opportunities.

Theodora Lee Joseph, CFA. First and foremost a long-term investor, and previously spent nine years at Goldman Sachs as an equity research analyst covering European Oil & Gas and chemicals companies.

Stéphane Renevier, CFA. Started out as a multi-asset analyst at British fund manager Schroders, and later worked as a portfolio manager at Wells Fargo, where he managed long-short global macro strategies across all asset classes.

Independent in-depth research from Finimize

IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!

Finimize

Finimize is the #1 information platform for modern investors. We empower people to become smarter investors with bitesize insights from world-class analysts. 1 million+ strong community, 250 partners.

Equity Bottom-Up

<ul>
<li>IDEXX Laboratories,  a $35 billion company, is a global leader in veterinary diagnostics, selling and developing the tools that help vets diagnose and treat animals.</li>
<li>IDEXX operates a highly recurring, subscription-like business model, particularly in its Companion Animal Group (CAG), which accounts for over 90% of its revenue.</li>
<li>IDEXX is a cash-generating, high-return compounder at the center of a booming industry and stock looks undervalued right now.</li>
</ul>


IDEXX Laboratories,  a $35 billion company, is a global leader in veterinary diagnostics, selling and developing the tools that help vets diagnose and treat animals.
IDEXX operates a highly recurring, subscription-like business model, particularly in its Companion Animal Group (CAG), which accounts for over 90% of its revenue.
IDEXX is a cash-generating, high-return compounder at the center of a booming industry and stock looks undervalued right now.


IDEXX: Pet Healthcare Could Be An Investor's Best Friend